ImmuPharma (IMML) Stock Overview
A biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
IMML Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
ImmuPharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.065 |
| 52 Week High | UK£0.15 |
| 52 Week Low | UK£0.055 |
| Beta | 3.02 |
| 1 Month Change | 3.85% |
| 3 Month Change | -7.16% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -40.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| IMML | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -9.2% | -3.7% | -2.1% |
| 1Y | n/a | 22.3% | 21.6% |
Return vs Industry: Insufficient data to determine how IMML performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how IMML performed against the UK Market.
Price Volatility
| IMML volatility | |
|---|---|
| IMML Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.9% |
Stable Share Price: IMML's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine IMML's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 6 | Tim McCarthy | www.immupharma.co.uk |
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140, which is in Phase II clinical trial for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare acquired autoimmune disorder of peripheral nerve; and P140 that covers other indications acute and chronic asthma, gout, irritable bowel disease, and periodontitis.
ImmuPharma plc Fundamentals Summary
| IMML fundamental statistics | |
|---|---|
| Market cap | UK£33.88m |
| Earnings (TTM) | -UK£3.93m |
| Revenue (TTM) | n/a |
Is IMML overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMML income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£3.93m |
| Earnings | -UK£3.93m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0078 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IMML perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/12 04:38 |
| End of Day Share Price | 2026/03/09 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ImmuPharma plc is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Cavendish |
| Alexander Pye | Cavendish |
| Christian Glennie | Edison Investment Research |